Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia

25 March 2019
– Tildacerfont demonstrates meaningful reduction in key disease biomarkers adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP) and androstenedione (A4)
– Well-tolerated and safe, tildacerfont holds potential as a treatment for patients with congenital adrenal hyperplasia, a rare endocrine disorder

Read More +

Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)

08 March 2019
Tildacerfont demonstrates potential to become the first approved therapy for congenital adrenal hyperplasia, a rare endocrine disorder

Read More +

Neurocrine Shines In Congenital Adrenal Hyperplasia, But Competitor Is Close

13 March 2019
Spruce’s competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.

Read More +

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies to better serve patients with rare endocrine disorders. Our team has extensive experience with managing patients with rare endocrine diseases as well as developing novel therapeutics to treat patients with unmet needs. As a team, we are committed to transforming the quality of life for patients who have been underserved by scientific innovation.